Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Pax H.B. Willemse"'
Autor:
Sabine Siesling, Dick Reiding, Geertruida H. de Bock, Linda de Munck, Renée Otter, Pax H.B. Willemse, Mireille J. M. Broeders
Publikováno v:
British Jounal of Cancer, 115(5), 517-524. Nature Publishing Group
British Journal of Cancer
British journal of cancer, 115(5), 517-524. Nature Publishing Group
British Journal of Cancer
British journal of cancer, 115(5), 517-524. Nature Publishing Group
Background: Full-field digital mammography (FFDM) has replaced screen-film mammography (SFM) in most breast cancer screening programs due to technological advantages such as possibilities to adjust contrast, better image quality and transfer capabili
Autor:
Pax H.B. Willemse, Marian B. E. Menke-Pluijmers, Joost Bart, Sabine Siesling, Renée Otter, Linda de Munck
Publikováno v:
European journal of cancer prevention, 22(5), 398-403. LIPPINCOTT WILLIAMS & WILKINS
European journal of cancer prevention, 22(5), 398-403. Lippincott Williams and Wilkins
European journal of cancer prevention, 22(5), 398-403. Lippincott Williams and Wilkins
Positive tumour margins after breast-conserving surgery (BCS) have been selected as one of the major quality criteria for the surgical treatment of localized primary breast cancer. The national guideline states that the rate of positive margins shoul
Autor:
H. de Graaf, M. Polee, Anna K.L. Reyners, Willem M. Smit, A.N.M. Wymenga, Pax H.B. Willemse, Frans L. G. Erdkamp, M A T M van Vugt, Roy I. Lalisang, L. de Munck, K. Hoekman, Michael Schaapveld, Harry Hollema
Publikováno v:
Annals of Oncology, 23(11), 2896-2902. Oxford University Press
Reyners, A K L, de Munck, L, Erdkamp, F L G, Smit, W M, Hoekman, K, Lalisang, R I, de Graaf, H, Wymenga, A N M, Polee, M, Hollema, H, van Vugt, M A T M, Schaapveld, M & Willemse, P H B 2012, ' A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study ', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902 . https://doi.org/10.1093/annonc/mds107
Reyners, A K L, de Munck, L, Erdkamp, F L G, Smit, W M, Hoekman, K, Lalisang, R I, de Graaf, H, Wymenga, A N M, Polee, M, Hollema, H, van Vugt, M A T M, Schaapveld, M & Willemse, P H B 2012, ' A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study ', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902 . https://doi.org/10.1093/annonc/mds107
In ovarian cancer, cyclooxygenase-2 (COX-2) overexpression is prognostic for poor survival. We investigated the efficacy of celecoxib (C), a selective COX-2 inhibitor, added to docetaxel (Taxotere)/carboplatin (DC) in advanced ovarian cancer.In a pha
Autor:
Johannes A. Langendijk, Otto Visser, E.J. Bantema-Joppe, Pax H.B. Willemse, John H. Maduro, Sabine Siesling, Linda de Munck
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 81(4), E553-E559. ELSEVIER SCIENCE INC
International journal of radiation: Oncology-Biology-Physics, 81(4), e553-e559. Elsevier
International journal of radiation: Oncology-Biology-Physics, 81(4), e553-e559. Elsevier
PurposeIn young women, breast-conserving therapy (BCT), i.e., lumpectomy followed by radiotherapy, has been associated with an increased risk of local recurrence. Still, there is insufficient evidence that BCT impairs survival. The aim of our study w
Autor:
Gert A. van Deijk, Linda de Munck, Anneke M. Westermann, Willem M. Smit, Geert-Jan Creemers, Carolien P. Schröder, Willemijn Vader, Zoran Erjavec, Pax H.B. Willemse, Aart van Bochove, Hiltje de Graaf, Jacqueline M. Stouthard
Publikováno v:
European journal of cancer (Oxford, England, 47(9), 1355-1362. Elsevier Limited
European Journal of Cancer, 47(9), 1355-1362. ELSEVIER SCI LTD
European Journal of Cancer, 47(9), 1355-1362. ELSEVIER SCI LTD
Background: In anthracycline-pretreated metastatic breast cancer (MBC) patients, it is unknown whether weekly single-agent docetaxel is preferable to 3-weekly docetaxel regarding its toxicity and efficacy profile.Patients and methods: In this multice
Autor:
J. Marina Maurer, Peter Nieboer, C. H. Mom, Elisabeth G.E. de Vries, A. N.Mac Hteld Wymenga, H. Marike Boezen, Robert S. De Jong, Pax H.B. Willemse, Marian J.E. Mourits, Ciska Buijs
Publikováno v:
Breast Cancer Research and Treatment, 115(3), 573-580. Springer New York
Buijs, C, Mom, C H, Willemse, P H B, Marike Boezen, H, Maurer, J M, Wymenga, A N M H, De Jong, R S, Nieboer, P, De Vries, E G E & Mourits, M J E 2009, ' Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : A double-blind, randomized cross-over study ', Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 573-580 . https://doi.org/10.1007/s10549-008-0138-7
Breast Cancer Research and Treatment, 115(3), 573-580. SPRINGER
Buijs, C, Mom, C H, Willemse, P H B, Marike Boezen, H, Maurer, J M, Wymenga, A N M H, De Jong, R S, Nieboer, P, De Vries, E G E & Mourits, M J E 2009, ' Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : A double-blind, randomized cross-over study ', Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 573-580 . https://doi.org/10.1007/s10549-008-0138-7
Breast Cancer Research and Treatment, 115(3), 573-580. SPRINGER
Purpose Breast cancer patients with treatment-induced menopause experience frequent and severe hot flashes (HF). We compared venlafaxine and clonidine for the treatment of HF with regard to side effects, efficacy, quality of life and sexual functioni
Autor:
Ido P. Kema, Elisabeth G.E. de Vries, Thera P. Links, Wouter W. de Herder, H. Marike Boezen, A N Machteld Wymenga, Pax H.B. Willemse, Wim G. Meijer, Willibrord C. M. Weijmar-Schultz, Ellen van Ieperen, Anouk N A van der Horst-Schrivers
Publikováno v:
Neuroendocrinology, 89(2), 231-236. KARGER
Neuroendocrinology, 89(2), 231-236. Karger
Neuroendocrinology, 89(2), 231-236. Karger
Background: Sexual dysfunction is a poorly studied aspect of quality of life in patients with midgut carcinoid tumours. We investigated whether carcinoid patients experience sexual problems. Methods: Patients with metastatic midgut carcinoid tumours
Publikováno v:
CANCER TREATMENT REVIEWS. 34(7):640-655
Many hormonal modalities are available for breast cancer treatment, such as selective oestrogen receptor modulators (SERMs), aromatase inhibitors, progestins and luteinising hormone-releasing hormone (LHRH) agonists. The Long-term impact of these end
Autor:
Wendy Post, Thera P. Links, Anouk N A van der Horst-Schrivers, A N Machteld Wymenga, Ido P. Kema, Pax H.B. Willemse, Elisabeth G.E. de Vries
Publikováno v:
European Journal of Cancer, 43(18), 2651-2657. ELSEVIER SCI LTD
Survival of patients with disseminated midgut carcinoid tumours varies. We investigated which factors predict survival at referral and during follow-up, with emphasis on urinary 5-hydroxyindolacetic acid (5-HIAA) levels. Between 1992 and 2003, 76 pat
Autor:
Youlia M. Kirova, Piotr J. Wysocki, Judy W. C. Ho, Ute Hamann, Dominique Stoppa-Lyonnet, Fernando Schmitt, Gulnur Guler, Zheng Shu, Neva E. Haites, Peter Simmonds, Cornelis J.M. Lips, Janis Gardovskis, Alain Fourquet, Evangelia Razis, Jean-Yves Pierga, Johannes W. B. de Groot, Siniša Radulović, Kay Huebner, Diana Eccles, Lidia Larizza, Åke Borg, Niklas Loman, Thangarajan Rajkumar, Peter T. Silberstein, Rita K. Schmutzler, Arvids Irmejs, Håkan Olsson, Rolf H. Sijmons, Lenka Foretova, Evgeny N. Imyanitov, Winette T. A. van der Graaf, Henry T. Lynch, Pål Møller, Pax H.B. Willemse, Pavel Elsakov, Vladimir Zajac, Jae-Gahb Park, Jacob Smeltzer, Walter P. Weber, P. Goetz, Mira Brankovic-Magic, Marianna Bitina, Gunta Purkalne, Andris Gardovskis, Drakoulis Yannoukakos
Publikováno v:
Hereditary Cancer in Clinical Practice
Hereditary cancer in clinical practice, 5(3), 119-143. BioMed Central Ltd.
Hereditary cancer in clinical practice, 5(3), 119-143. BioMed Central Ltd.
BRCA1-associated cancers differ from non-hereditary cancers for many factors, including somatic mutation. It can be a subject of discussion that the natural history and response to treatment also may differ between the hereditary and sporadic subgrou